NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04524273,Myasthenia Gravis Inebilizumab Trial,https://clinicaltrials.gov/study/NCT04524273,MINT,ACTIVE_NOT_RECRUITING,"Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.",NO,Myasthenia Gravis,DRUG: inebilizumab|DRUG: IV Placebo,"Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Profile score., Baseline to Week 26","Change from baseline in Quantitative Myasthenia Gravis (QMG) scores., Baseline to Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Proportion of participants with both ≥ 3-point improvement from baseline in MG-ADL and did not initiate rescue therapy., Baseline to Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Change from baseline in MG-ADL, Baseline to Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Time to first gMG exacerbation., Day 1 to Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Change from baseline in Myasthenia Gravis Composite (MGC) score., Baseline to Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Change from baseline in Myasthenia Gravis Quality of Life-15, revised (MGQOL-15r) score., Baseline to Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Patient Global Impression of Change (PGIC) score., Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Number of participants with treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and treatment-emergent serious adverse events (TESAEs) during the RCP and OLP., Up to 208 weeks|Proportion of participants with steroid tapered to ≤ 5 mg/day., Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Proportion of participants with a steroid dose reduction from baseline of ≥ 50%., Baseline to Week 52 for AChR-Ab+ population and Week 26 for the overall study population|Proportion of participants achieving minimal symptom expression., Minimal symptom expression was defined as an MG-ADL of 0 or 1., Week 26|Proportion of participants with anti-drug antibodies (ADAs) to inebilizumab, Up to 208 weeks|Titers of ADAs, Up to 208 weeks",,Amgen,,ALL,"ADULT, OLDER_ADULT",PHASE3,238,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",VIB0551.P3.S1,2020-10-15,2024-05-28,2027-11-29,2020-08-24,,2025-02-20,"Viela Bio Investigative Site - 1015, Orange, California, 92868, United States|Viela Bio Investigative Site - 1002, New Haven, Connecticut, 06519, United States|Viela Bio Investigative Center - 1024, Washington, District of Columbia, 20010, United States|Viela Bio Investigative Site - 1005, Tampa, Florida, 33612, United States|Viela Bio Investigative Site - 1012, Kansas City, Kansas, 66160, United States|Viela Bio Investigative Site - 1018, Charlotte, North Carolina, 28203, United States|Viela Bio Investigative Site - 1025, Canton, Ohio, 44718, United States|Viela Bio Investigative Site - 1001, Cincinnati, Ohio, 45219, United States|Viela Bio Investigative Site - 1009, Columbus, Ohio, 43210, United States|Viela Bio Investigative Site - 1008, Pittsburgh, Pennsylvania, 15212, United States|Viela Bio Investigative Site - 1019, Austin, Texas, 78759, United States|Viela Bio Investigative Site - 1003, Houston, Texas, 77030, United States|Viela Bio Investigative Site - 1014, San Antonio, Texas, 78229, United States|Viela Bio Investigative Site - 1017, Salt Lake City, Utah, 84132, United States|Viela Bio Investigative Site - 1004, Burlington, Vermont, 05401, United States|Viela Bio Investigative Site - 1006, Richmond, Virginia, 23298, United States|Viela Bio Investigative Site - 2001, Buenos Aires, C1023AAB, Argentina|VielaBio Investigative Site - 2002, Buenos Aires, C1199ABB, Argentina|Viela Bio Investigative Site - 2003, Buenos Aires, C1221ADC, Argentina|Viela Bio Investigative Site - 5203, Grodno, 230030, Belarus|Viela Bio Investigative Site - 5204, Minsk, 220114, Belarus|Viela Bio Investigative Site - 5201, Vitebsk, 210009, Belarus|VielaBio Investigative Site - 2201, Porto Alegre, 90035-001, Brazil|VielaBio Investigative Site - 2203, Porto Alegre, 90840-440, Brazil|VielaBio Investigative Site - 2207, Ribeirão Preto, 14051-140, Brazil|VielaBio Investigative Site - 2206, San Paolo, 01228-000, Brazil|Viela Bio Investigative Site - 2205, São Paulo, 08270-120, Brazil|Viela Bio Investigative Site - 1102, Toronto, Ontario, M5G 2C4, Canada|Viela Bio Investigative Site - 1101, Montréal, Quebec, H2X 3J4, Canada|Viela Bio Investigative Site - 1103, Montréal, Quebec, H3A 2B4, Canada|Viela Bio Investigative Site 4009, Beijing, 100029, China|Viela Bio Investigative Site - 4007, Beijing, 100053, China|Viela Bio Investigative Site 4003, Beijing, 100070, China|Viela Bio Investigative Site - 4005, Guiyang, 550004, China|Viela Bio Investigative site 4010, Hunan, 410008, China|Viela Bio Investigative Site - 4011, Jinan, 250012, China|Viela Bio Investigative Site - 4006, Shanghai, 201107, China|Viela Bio Investigative Site - 4008, Suzhou, 215006, China|Viela Bio Investigative Site - 4004, Tianjin, 300052, China|Viela Bio Investigative Site 4012, Xi'an, 710038, China|Viela Bio Investigative Site - 5601, Copenhagen, 2100, Denmark|Viela Bio Investigative Site - 3003, Lille Cedex, 59037, France|Viela Bio Investigative Site - 3001, Nice Cedex 01, 06001, France|Viela Bio Investigative Site - 3002, Strasbourg, 67098, France|VielaBio Investigative Site - 3101, Essen, 45122, Germany|Viela Bio Investigative Site - 4107, Nagpur, Maharashtra, 440003, India|Viela Bio Investigative Site - 4113, Nagpur, Maharashtra, 440012, India|Viela Bio Investigative Site - 4112, Hyderabad, Telangana, 500082, India|Viela Bio Investigative Site - 4104, Bangalore, 560002, India|Viela Bio investigative Site - 4105, Lucknow, 226014, India|Viela Bio Investigative Site - 4103, Manipala, 576104, India|Viela Bio Investigative Site - 4102, Nashik, 422002, India|Viela Bio Investigative Site - 4109, Pune, 411004, India|Viela Bio Investigative Site - 4101, Surat, 395002, India|Viela Bio Investigative Site - 3204, Milano, 20122, Italy|Viela Bio Investigative Site - 3203, Milano, 20133, Italy|Viela Bio Investigative Site - 3201, Pavia, 27100, Italy|Viela Bio Investigative Site - 3202, Rome, 168, Italy|Viela Bio Investigative Site - 4402, Chiba, 260-8677, Japan|Viela Bio Investigative Site - 4410, Chiba, 286-8520, Japan|Viela Bio Investigative Site 4409, Fukuoka, 812-8582, Japan|Viela Bio Investigative Site - 4401, Hanamaki, 025-0082, Japan|VielaBio Investigative Site - 4408, Hokkaido, 041-8680, Japan|Viela Bio Investigative Site - 4406, Hyōgo, 663-8501, Japan|Viela Bio Investigative Site 4405, Miyagi, 983-8520, Japan|Viela Bio Investigative Site - 4413, Moriguchi, 570-8507, Japan|VielaBio Investigative Site - 4407, Morioka-shi, 020-8505, Japan|Viela Bio Investigative Site - 4404, Saitama, 350-8550, Japan|Viela Bio Investigative Site - 4202, Seoul, 3722, Korea, Republic of|Viela Bio Investigative Site - 4203, Seoul, 5030, Korea, Republic of|Viela Bio Investigative Site - 4201, Seoul, 6351, Korea, Republic of|Viela Bio Investigative Site - 3302, Katowice, 40-635, Poland|Viela Bio Investigative Site - 3303, Katowice, 40-752, Poland|Viela Bio Investigative Site - 3301, Kraków, 31-505, Poland|Med Polonia Sp. z o.o - 3311, Poznań, 60-693, Poland|Viela Bio Investigative Site - 3310, Warszawa, 01-868, Poland|Viela Bio Investigative Site - 5313, Barnaul, Altai Krai, 656043, Russian Federation|Viela Bio Investigative Site - 5303, Barnaul, 656045, Russian Federation|Viela Bio Investigative Site - 5302, Nizhny Novgorod, 603126, Russian Federation|Viela Bio Investigative Site - 5304, Novosibirsk, 630087, Russian Federation|Viela Bio Investigative Site - 5311, Rostov-on-Don, 344015, Russian Federation|Viela Bio Investigative Site - 5309, Rostov-on-Don, 344022, Russian Federation|Viela Bio Investigative Site - 5308, Saint Petersburg, 197110, Russian Federation|Viela Bio Investigative Site - 5305, Samara, 443095, Russian Federation|Viela Bio Investigative Site - 5312, Ufa, 450083, Russian Federation|Viela Bio Investigative Site - 3403, Badalona, 8916, Spain|Viela Bio Investigative Site - 3402, Barcelona, 8003, Spain|Viela Bio Investigative Site - 3404, Córdoba, 14004, Spain|Viela Bio investigative Site - 4605, Kaohsiung City, 83301, Taiwan|Viela Bio Investigative Site 4608, New Taipei City, 235, Taiwan|Viela Bio Investigative Site - 4606, Tainan, 704, Taiwan|Viela Bio Investigative Site - 4604, Taipei, 10002, Taiwan|Viela Bio Investigative Site - 4603, Taipei, 111, Taiwan|Viela Bio Investigative Site -4607, Taipei, 11217, Taiwan|Viela Bio Investigative Site - 4602, Taoyuan City, 333, Taiwan|Viela Bio Investigative Site - 3903, Ankara, 6230, Turkey|Viela Bio Investigative Site - 3901, İzmir, 35100, Turkey|Viela Bio Investigative Site - 3902, İzmir, 35330, Turkey|Viela Bio Investigative Site - 3905, Kocaeli, 41380, Turkey|Viela Bio Investigative Site - 5103, Dnipro, 49005, Ukraine|Viela Bio Investigative Site - 5108, Dnipro, 49089, Ukraine|Viela Bio Investigative Site - 5105, Ivano-Frankivs'k, 76493, Ukraine|Viela Bio Investigative Site - 5104, Lutsk, 43005, Ukraine|Viela Bio Investigative Site - 5106, Vinnytsia, 21050, Ukraine",
